Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD

3.01  -0.25 (-7.67%)

After market: 3.06 +0.05 (+1.66%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ORGO. ORGO was compared to 561 industry peers in the Biotechnology industry. ORGO scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ORGO has a decent growth rate and is not valued too expensively. These ratings could make ORGO a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

ORGO had positive earnings in the past year.
In the past year ORGO had a positive cash flow from operations.
ORGO had positive earnings in 4 of the past 5 years.
In the past 5 years ORGO always reported a positive cash flow from operatings.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

The Return On Assets of ORGO (-0.19%) is better than 89.66% of its industry peers.
The Return On Equity of ORGO (-0.24%) is better than 91.09% of its industry peers.
ORGO's Return On Invested Capital of 4.04% is amongst the best of the industry. ORGO outperforms 92.69% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ORGO is significantly below the industry average of 15.87%.
The last Return On Invested Capital (4.04%) for ORGO is above the 3 year average (3.79%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.19%
ROE -0.24%
ROIC 4.04%
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

ORGO has a better Operating Margin (4.46%) than 92.69% of its industry peers.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO has a Gross Margin of 75.99%. This is amongst the best in the industry. ORGO outperforms 83.07% of its industry peers.
ORGO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.46%
PM (TTM) N/A
GM 75.99%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ORGO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ORGO has more shares outstanding
ORGO has a better debt/assets ratio than last year.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 3.70 indicates that ORGO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.70, ORGO is in the better half of the industry, outperforming 77.36% of the companies in the same industry.
ORGO has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
ORGO has a better Debt to FCF ratio (0.45) than 96.26% of its industry peers.
ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, ORGO perfoms like the industry average, outperforming 46.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Altman-Z 3.7
ROIC/WACC0.39
WACC10.38%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ORGO has a Current Ratio of 3.69. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ORGO (3.69) is comparable to the rest of the industry.
A Quick Ratio of 3.35 indicates that ORGO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.35, ORGO is in line with its industry, outperforming 40.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 3.35
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 125.00% over the past year.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
The Revenue has grown by 11.29% in the past year. This is quite good.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%

3.2 Future

The Earnings Per Share is expected to grow by 12.13% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.02% on average over the next years. This is quite good.
EPS Next Y-77.5%
EPS Next 2Y0%
EPS Next 3Y12.13%
EPS Next 5YN/A
Revenue Next Year4.27%
Revenue Next 2Y8.2%
Revenue Next 3Y10.02%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 33.44, the valuation of ORGO can be described as expensive.
Based on the Price/Earnings ratio, ORGO is valued cheaply inside the industry as 93.40% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ORGO to the average of the S&P500 Index (26.03), we can say ORGO is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 17.71, the valuation of ORGO can be described as rather expensive.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 92.69% of the companies are valued more expensively.
ORGO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.44
Fwd PE 17.71
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 97.86% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 92.87% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 91.43
EV/EBITDA 7.26
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

ORGO has a very decent profitability rating, which may justify a higher PE ratio.
ORGO's earnings are expected to grow with 12.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y12.13%

More info and screens

0

5. Dividend

5.1 Amount

ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (5/21/2025, 7:05:00 PM)

After market: 3.06 +0.05 (+1.66%)

3.01

-0.25 (-7.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners50.15%
Inst Owner Change5.69%
Ins Owners30.6%
Ins Owner Change0.99%
Market Cap381.82M
Analysts82
Price Target6.12 (103.32%)
Short Float %17.44%
Short Ratio6.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)629.41%
Min EPS beat(2)570.59%
Max EPS beat(2)688.24%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.53%
Min Revenue beat(2)3.75%
Max Revenue beat(2)13.3%
Revenue beat(4)4
Avg Revenue beat(4)7.13%
Min Revenue beat(4)3.75%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)3.01%
Revenue beat(12)5
Avg Revenue beat(12)0.76%
Revenue beat(16)8
Avg Revenue beat(16)2.27%
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1233.4%
EPS NY rev (1m)0%
EPS NY rev (3m)150%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.86%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)2.66%
Valuation
Industry RankSector Rank
PE 33.44
Fwd PE 17.71
P/S 0.79
P/FCF 91.43
P/OCF 26.87
P/B 0.99
P/tB 1.11
EV/EBITDA 7.26
EPS(TTM)0.09
EY2.99%
EPS(NY)0.17
Fwd EY5.65%
FCF(TTM)0.03
FCFY1.09%
OCF(TTM)0.11
OCFY3.72%
SpS3.8
BVpS3.04
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.19%
ROE -0.24%
ROCE 5.12%
ROIC 4.04%
ROICexc 5.97%
ROICexgc 6.98%
OM 4.46%
PM (TTM) N/A
GM 75.99%
FCFM 0.87%
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Debt/EBITDA 0.02
Cap/Depr 58.92%
Cap/Sales 2.08%
Interest Coverage 4.33
Cash Conversion 36.86%
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 3.35
Altman-Z 3.7
F-Score6
WACC10.38%
ROIC/WACC0.39
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-77.5%
EPS Next 2Y0%
EPS Next 3Y12.13%
EPS Next 5YN/A
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year4.27%
Revenue Next 2Y8.2%
Revenue Next 3Y10.02%
Revenue Next 5YN/A
EBIT growth 1Y71.72%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year454.35%
EBIT Next 3Y72.88%
EBIT Next 5YN/A
FCF growth 1Y-36.27%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-54.04%
OCF growth 3Y-38.8%
OCF growth 5YN/A